Get started
Author

Tengiz Tsertsvadze

Observed names: T N Tsertsvadze, T Tsertsvadze, T. Tsertsvadze, TENGIZ TSERTSVADZE, Tengiz TSERTSVADZE, Tengiz Tsertswadze, Tergiz Tsertsvadze, Tsertsvadze, T, Tsertsvadze, Tengiz
Observed institutions: Tbilisi State University, National Center for Disease Control and Public Health, Johns Hopkins University, United States Army Medical Research Institute of Infectious Diseases, World Health Organization, AIDS and Clinical Immunology Research Center, Naval Medical Research Unit EURAFCENT, Center for Surveillance, Epidemiology, and Laboratory Services, Institut für Mikrobiologie der Bundeswehr, Pathobiologie et thérapie des maladies du foie, Service de Recherches en Hémato-Immunologie, Tbilisi State Medical University, Walter Reed Army Institute of Research
ORCID: 0000-0002-4986-7874
Observed ORCID: 0000-0002-4986-7874
OpenAlex ID: A5035151513
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
2022 · Hongchao Pan, Richard Peto, et al. · The Lancet · 394
PDF
Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis
2018 · Jack Stone, Hannah Fraser, et al. · The Lancet Infectious Diseases · 225
PDF
Launch of a Nationwide Hepatitis C Elimination Program — Georgia, April 2015
2015 · Kiren Mitruka, Tengiz Tsertsvadze, et al. · MMWR Morbidity and Mortality Weekly Report · 106
PDF
Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience
2017 · Ekaterine Dolmazashvili, Akaki Abutidze, et al. · European Journal of Gastroenterology & Hepatology · 82
National Progress Toward Hepatitis C Elimination — Georgia, 2015–2016
2016 · Lia Gvinjilia, Muazzam Nasrullah, et al. · MMWR Morbidity and Mortality Weekly Report · 75
PDF
Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia
2006 · Ekaterine Shapatava, Kenrad E. Nelson, et al. · Drug and Alcohol Dependence · 73
Prevalence and risk factors for latent tuberculosis infection among health care workers in Georgia.
2008 · V Mirtskhulava, R Kempker, et al. · PubMed · 69
Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia
2019 · Francisco Averhoff, Shaun Shadaker, et al. · Journal of Hepatology · 61
The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19
2022 · ACTIV-3/TICO Study Group, Angela J. Rogers, et al. · Annals of Internal Medicine · 60
PDF
The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination — Georgia, 2015–2016
2017 · Muazzam Nasrullah, David Sergeenko, et al. · MMWR Morbidity and Mortality Weekly Report · 60
PDF
Etiology of neonatal blood stream infections in Tbilisi, Republic of Georgia
2008 · Nino Macharashvili, Ekaterina Kourbatova, et al. · International Journal of Infectious Diseases · 60
PDF
Prevalence of hepatitis B, hepatitis C, syphilis and HIV in Georgian blood donors
2001 · M. Butsashvili, T. Tsertsvadze, et al. · European Journal of Epidemiology · 54
Assessment of quality of life in people living with HIV in Georgia
2016 · Ekaterine Karkashadze, Margaret A. Gates, et al. · International Journal of STD & AIDS · 49
Prevalence of Hepatitis C, HIV, and Risk Behaviors for Blood-Borne Infections: A Population-Based Survey of the Adult Population of T'bilisi, Republic of Georgia
2006 · Ketevan Stvilia, Tengiz Tsertsvadze, et al. · Journal of Urban Health · 48
Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015–March 2018
2019 · Tengiz Tsertsvadze, Amiran Gamkrelidze, et al. · Clinical Infectious Diseases · 41
HIV-1 Genetic Diversity and Genotypic Drug Susceptibility in the Republic of Georgia
2006 · Maia Zarandia, Tengiz Tsertsvadze, et al. · AIDS Research and Human Retroviruses · 37
Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset
2019 · J. Morgan Freiman, Jianing Wang, et al. · Journal of Hepatology · 36
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting
2020 · Lauren Greenberg, Lene Ryom, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 35
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19
2022 · ACTIV-3/TICO Study Group*, Christina Barkauskas, et al. · Annals of Internal Medicine · 31
PDF
Mortality and Causes of Death Among HIV-Infected Individuals in the Country of Georgia: 1989–2012
2014 · Nikoloz Chkhartishvili, Lali Sharvadze, et al. · AIDS Research and Human Retroviruses · 29
Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients
2007 · Mark H. Kuniholm, Jennifer Mark, et al. · International Journal of Infectious Diseases · 29
PDF
Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study
2019 · Josephine G Walker, Tinatin Kuchuloria, et al. · The Lancet Global Health · 28
PDF
Excellence in viral hepatitis elimination – Lessons from Georgia
2019 · Francisco Averhoff, Jeffrey V. Lazarus, et al. · Journal of Hepatology · 28
PDF
Risk Factors for Hepatitis C Virus Infection among Blood Donors in Georgia
2004 · Nickolas Zaller, Kenrad E. Nelson, et al. · European Journal of Epidemiology · 28
High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment
2015 · Marine Karchava, Jesper Waldenström, et al. · Hepatology Research · 27
Works count: 165
Citation count: 2,510
H-index: 26
I10-index: 56
Year
Topic
Type